Arturo Penco

Dr. Arturo Penco

University of Trieste, Trieste, Friuli-Venezia Giulia, Italy
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2022 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
MPMartina Peinkhofer
Martina Peinkhofer
BBBenedetta Bossini
Benedetta Bossini
APArturo Penco
Arturo Penco
MGManuela Giangreco
Manuela Giangreco
MPMaria Chiara Pellegrin
Maria Chiara Pellegrin
GTGianluca Tornese
Gianluca Tornese
Background: While several studies have been published so far on the effect of COVID-19 pandemic on health care for non-COVID-19 diseases, to date no study evaluated the impact of the COVID-19 pandemic on the entire field of pediatric endocrinology. This study aimed to evaluate differences in pediatric endocrine stimulation tests after the advent of COVID-19 pandemics. Methods: Retrospective study with data collection for pediatric endocrine stimulation tests performed in 2019 and 2020 in a tertiary center. Results: Overall, 251 tests were performed on 190 patients in 2020, compared to 278 tests on 206 patients in 2019 (− 10% tests; − 8% children evaluated). A significant reduction was found in tests to diagnose growth hormone deficiency (GHD) (− 35%), while LHRH tests increased (+ 22%). A reduction of 30% in GHD diagnosis was observed. Central precocious puberty (CPP) diagnosis increased by 38% compared to 2019, mainly in females. Conclusion: This study found a significant reduction of tests investigating GHD during COVID-19 pandemics. It also showed a clinically meaningful increase in cases of CPP in girls. These results suggest the need for families and pediatricians to monitor children’s growth during isolation and enlighten new perspectives towards conditions associated with lockdown restrictions as increased screen time, social isolation, and children’s anxiety as possible triggers of CPP.

19 May 2021 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
APArturo Penco
Arturo Penco
EBEgidio Barbi
Egidio Barbi

7 May 2022 in Children
Verified
Journal Article
Open access
PDF file
MPMaria Chiara Pellegrin
Maria Chiara Pellegrin
APArturo Penco
Arturo Penco
LALeonardo Amadio
Leonardo Amadio
SNSamuele Naviglio
Samuele Naviglio
LLLuigina De Leo
Luigina De Leo
Lorenzo MonastaLorenzo Monasta
Lorenzo Monasta
Serious bacterial infections (SBI) in children are associated with considerable morbidity and mortality, and their early identification remains challenging. The role of laboratory tests in this setting is still debated, and new biomarkers are needed. This prospective, observational, single-center study aims to evaluate the diagnostic role of blood biomarkers in detecting SBI in children presenting with signs of systemic inflammatory response syndrome (SIRS). A panel of biomarkers was performed, including C-reactive protein (CRP), procalcitonin (PCT), white blood cell count (WBC), absolute neutrophil count (ANC), interleukin (IL)-6, IL-8, IL-10, human terminal complement complex (C5b-9), Plasmalemma-Vesicle-associated protein 1 (PV-1), Intercellular Adhesion Molecule-1 (ICAM-1), and Phospholipase A2 (PLA2). Among 103 patients (median age 2.9 years, 60% males), 39 had a diagnosis of SBI (38%). Significant predictors of SBI were CRP (p = 0.001) and ICAM-1 (p = 0.043). WBC (p = 0.035), ANC (p = 0.012) and ANC/WBC ratio (p = 0.015) were also significantly associated with SBI in children without pre-existing neutropenia. ROC curves, however, revealed suboptimal performance for all variables. Nevertheless, a model that combined CRP and ANC/WBC ratio had more in-depth diagnostic accuracy than either of the two variables. Overall, this study confirms the limited usefulness of blood biomarkers for the early diagnosis of SBI. WBC, ANC, ANC/WBC ratio, CRP, and ICAM-1 showed the best, albeit moderate, diagnostic accuracy.

15 November 2021 in Medico e Bambino
Verified
Journal Article
Closed access
APArturo Penco
Arturo Penco
FPFrancesca Peri
Francesca Peri
FPFederico Poropat
Federico Poropat
ECEster Conversano
Ester Conversano
EBEgidio Barbi
Egidio Barbi
GCGiorgio Cozzi
Giorgio Cozzi
Fasting before procedural sedation is a hot topic in everyday medical life with the main concern regarding pulmonary aspiration. Fasting guidelines before procedural sedation have always been the same as those used for general anaesthesia. However, procedural sedation and general anaesthesia differ in terms of invasiveness, drugs, duration and patient characteristics. This results in lower risk of pulmonary aspiration during procedural sedation, when compared to general anaesthesia. Moreover, a large case series of sedations performed in the emergency department with no respect for the proper fasting times showed no association between fasting duration and any type of adverse event with the latter occurring also in patients that properly fasted. The type of procedure (with the need of airway management) and characteristics of the patient seem to matter more. Furthermore, prolonged fasting is uncomfortable and has been associated with hypoglycaemia and dehydration. For this reason, fasting guidelines before procedural sedation should be adapted on the presence of risk factors, such as ASA score, need for airway management, comorbidities, type of procedure and drug used.

25 November 2020 in Research Square
Verified
Preprint
Open access
PDF file
MPMaria Chiara Pellegrin
Maria Chiara Pellegrin
APArturo Penco
Arturo Penco
LALeonardo Amadio
Leonardo Amadio
SNSamuele Naviglio
Samuele Naviglio
LLLuigina De Leo
Luigina De Leo
Lorenzo MonastaLorenzo Monasta
Lorenzo Monasta
BACKGROUND: Serious bacterial infections (SBI) in children are still associated with considerable morbidity and mortality. Early identification of SBI in children presenting with fever and/or signs of systemic inflammatory response (SIRS) remains challenging, as clinical presentation may be subtle, and the role of laboratory markers is still debated. The purpose of the present study is to evaluate the diagnostic role of established and candidate blood biomarkers for the early discrimination of SBI in pediatric patients presenting with fever and/or SIRS criteria.METHODS: Children who met SIRS criteria and had the clinical indication to perform blood sampling at the first medical evaluation were consecutively enrolled. A panel of biomarkers was performed at enrolment, including C-reactive protein, procalcitonin, white blood cell count (WBC), absolute neutrophil count (ANC), interleukin (IL)-6, IL-8, IL-10, human terminal complement complex (C5b-9), Plasmalemma-Vesicle-associated protein 1 (PV-1), Intercellular Adhesion Molecule-1 (ICAM-1), and Phospholipase A2 (PLA2). Bivariate logistic regression models were created to identify significant predictors of SBI. RESULTS: Among 103 patients (median age 2.9 years, 60% males), 39 had a diagnosis of SBI (38%). Significant predictors of SBI were CRP (p=0.001) and ICAM-1 (p=0.043). In the subgroup of patients who were not immunocompromised because of a pre-existing medical condition or therapy (e.g. children with cancer and chemotherapy-induced neutropenia), significant predictors of SBI, were CRP (p=0.001) and ICAM-1 (p=0.037), WBC (p=0.035), ANC (p=0.012) and ANC/WBC ratio (p=0.015). The diagnostic performance of each variable as evaluated by means of ROC curves revealed suboptimal performance for all variables. A model combining CRP and ANC/WBC ratio, however, had a greater diagnostic accuracy than each one of the two variables. CONCLUSION: This study confirmed the limited usefulness of blood biomarkers for early diagnosis of SBI. WBC, ANC, ANC/WBC ratio, CRP and ICAM-1 showed the best, albeit moderate, diagnostic accuracy as single marker. At present, clinical judgement remains the mainstay for the diagnosis of SBIs in children.

14 September 2024 in European Respiratory Journal
Verified
Conference Paper
Closed access
APArturo Penco
Arturo Penco
SRSimone Ramazzotti
Simone Ramazzotti
SGSergio Ghirardo
Sergio Ghirardo
LMLaura Mazzari
Laura Mazzari
ATArianna Traunero
Arianna Traunero
MMMassimo Maschio
Massimo Maschio
Background: Elexacaftor-Tezacaftor-Ivacaftor (ELX/TEZ/IVA) has been tested in clinical trials and it is highly effective for patients with cystic fibrosis (CF) with at least one F508del allele, with improvements in sweat chloride, pulmonary function and nutrition. Objective: The aim of the study is to establish the efficacy of ELX/TEZ/IVA in a real-life setting. Methods: A prospective, observational study was conducted in the regional center of Friuli-Venezia-Giulia (Italy). 61 patients were enrolled. They were assessed 6 and 12 months after starting the therapy. 14 patients had a period of follow-up of 24 months. Outcomes included changes in percent predicted FEV1 (ppFEV1), sweat chloride concentration [Cl-], body mass index (BMI), quality of life, glycated hemoglobin (HbA1c), Oral Glucose Tolerance Test (OGTT) and Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Comparations were made in patients >12 years with 6-11 years and in patients previously treated with Lumacaftor-Ivacaftor with patients who were not. Results: Average age was 18 years. At 6 months ppFEV1 improved by 21 points and it was stable at 12 and 24 months. Significative improvements were observed in [Cl-], BMI, ESR, CRP, quality of life and number of pulmonary exacerbations. The changes were greater in patients not previously treated with modulators and in patients older than 12 years but they were substantial in all groups. No significant changes were observed in OGTT and HbA1c. Conclusions: Treatment with ELX/TEZ/IVA effectively improved lung function, BMI, sweat chloride concentration, markers of systemic inflammation and number of pulmonary exacerbations in real-life clinical practice.